[Effects of GLP-1 receptor agonists on carbohydrate metabolism control]

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists are a new group of drugs for the treatment of type 2 diabetes mellitus (DM2). In the present article, we review the available evidence on the efficacy of GLP-1 receptor agonists as glucose-lowering agents, their place in therapeutic algorithms, and the clinical factors associated with a favorable treatment response. Finally, we describe the clinical characteristics of patients who may benefit from these drugs.

Keywords: Agonista del receptor del péptido similar al glucagón; Diabetes; Diabetes mellitus; Efficacy; Eficacia; Exenatida; Exenatida semanal; Exenatide; Glucagon-like peptide-1 receptor agonist; Hipertensión; Hipoglucemias; Hypertension; Hypoglycemias; Liraglutida; Liraglutide; Lixisenatida; Lixisenatide; Obesidad; Obesity; Weekly exenatide.